

Development of Urea-Bond-Containing Michael Acceptors as Antitrypanosomal Agents Targeting Rhodesain

Santo Previti,* Roberta Ettari, Elsa Calcaterra, Carla Di Chio, Rahul Ravichandran, Collin Zimmer, Stefan Hammerschmidt, Annika Wagner, Marta Bogacz, Sandro Cosconati, Tanja Schirmeister, and Maria Zappalà



Cite This: *ACS Med. Chem. Lett.* 2022, 13, 1083–1090



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: Human African Trypanosomiasis (HAT) is a neglected tropical disease widespread in sub-Saharan Africa. Rhodesain, a cysteine protease of *Trypanosoma brucei rhodesiense*, has been identified as a valid target for the development of anti-HAT agents. Herein, we report a series of urea-bond-containing Michael acceptors, which were demonstrated to be potent rhodesain inhibitors with K_i values ranging from 0.15 to 2.51 nM, and five of them showed comparable k_{2nd} values to that of K11777, a potent antitrypanosomal agent. Moreover, most of the urea derivatives exhibited single-digit micromolar activity against the protozoa, and the presence of substituents at the P3 position appears to be essential for the antitrypanosomal effect. Replacement of Phe with Leu at the P2 site kept unchanged the inhibitory properties. Compound 7 (SPR7) showed the best compromise in terms of rhodesain inhibition, selectivity, and antiparasitic activity, thus representing a new lead compound for future SAR studies.

KEYWORDS: rhodesain, sleeping sickness, Michael acceptors, urea bond, antitrypanosomal



Human African Trypanosomiasis, also known by its acronym HAT or sleeping sickness, is a vector-borne Neglected Tropical Disease (NTD) caused by protozoa of *Trypanosoma brucei* (*T. b.*) species, widespread in sub-Saharan Africa.^{1,2} Two morphologically identical subspecies cause a different progression of the infection: *T. b. gambiense* is responsible for the chronic form of HAT characterized by slow development (gHAT); meanwhile, *T. b. rhodesiense* causes the acute form (rHAT).² The clinical manifestations of the disease were classified into two stages, namely, the hemolymphatic and neurological stages (stages 1 and 2, respectively).^{3,4} During stage 1, the protozoa, inoculated by the tsetse fly bite, mainly remain in the hemolymphatic system, spleen, and interstitial spaces, resulting in nonspecific symptoms, such as fever and general malaise.^{5,6} Subsequently, for still unclear reasons, the protozoa cross the blood-brain barrier (BBB) and invade the central nervous system (CNS), giving rise to stage 2, which is characterized by severe neurological problems, such as mental confusion, delirium, coma, and, last, death.^{7,8} As mentioned above, the two forms of HAT deeply differ in the disease manifestation progression: in fact, while gHAT can last for years, rHAT is characterized by a rapid progression (4–5 weeks) and higher mortality rate.⁹ To date, chemotherapy is the sole strategy to treat the infection: suramin, pentamidine, melarsoprol, and eflornithine were largely employed in the last century with modest results, mainly due to their toxicity, narrow-spectrum activity, and onset of resistance.^{10,11} In the last decades, nifurtimox, a well-known nitrofurane used to treat

Chagas disease, was off-label employed in combination with eflornithine for the treatment of the neurological stage of gHAT.¹¹ More recently, the nitroimidazole derivative fexinidazole was approved by the U.S. Food and Drug Administration (FDA) for the treatment of both stages of gHAT.^{12,13} At present, the enormous efforts made by the World Health Organization (WHO), Drugs for Neglected Diseases Initiative (DNDi), and charitable foundations have led to a significant decrease in HAT cases and related deaths.¹⁴ Despite that, the data collected could be underestimated due to the difficulty in reaching the most remote African regions. Furthermore, the possibility to easily move worldwide could spread the disease in nonendemic countries.^{15,16} Last but not least, both Nifurtimox-Eflornithine Combination Therapy (NECT) and fexinidazole were approved against gHAT, while the most aggressive and lethal rHAT does not have a drug of choice.^{11,12}

Starting from these considerations, the efforts of medicinal chemists were focused on the identification of novel approaches for HAT treatment. For this purpose, several

Received: February 25, 2022

Accepted: June 21, 2022

Published: June 30, 2022



review articles report innovative and valid strategies useful for the identification of novel targets and antitrypanosomal agents.^{17–19} In this context, rhodesain, a cysteine protease of *T. b. rhodesiense*, turned out to be one of the most promising targets for the development of antitrypanosomal agents.^{20–22} Rhodesain is a cathepsin L-like peptidase, also known as *Tbr*CatL,²³ which plays essential roles in the disease progression. This protozoal cathepsin is involved in BBB disruption, which promotes the progression of the disease to the neurological stage, and in the immunoevasion process, resulting in an ineffective host immune response.^{24,25} The proteolytic activity mediated by rhodesain occurs through the catalytic triad Cys/His/Asn, which is located in a cleft between the right (R) and left (L) domains,²⁶ once the enzyme's autoinhibitory pro-domain has undergone cleavage.²⁷ Considering its key functions, several classes of rhodesain inhibitors have been developed in recent years.²² The development of K11777 and K11002 (Figure 1), two potent peptide-based Michael acceptors with which rhodesain was cocrystallized (Protein Data Bank (PDB) ID: 2P7U and 2P86 for K11777 and K11002, respectively),^{26,28} has paved the way toward structure–activity relationship (SAR) studies of irreversible

rhodesain inhibitors.^{29–36} At the same time, molecules carrying several electrophilic portions, such as the nitroalkene, nitrile, 3-bromoisoxazoline, (het)arenes, and thiosemicarbazone groups, were developed as reversible rhodesain inhibitors.^{37–46}

In the last decades, we focused our efforts on the development of irreversible rhodesain inhibitors. In particular, the methyl vinyl ketone warhead was identified as the most reactive moiety if compared with vinyl-ester, -sulfone, and -cyano groups.^{34,35} The replacement of the methyl group with bulkier substituents led to analogues with a lower binding affinity toward rhodesain, and for this reason it was unchanged in the subsequent investigations.^{31,33} Similarly to K11777 and K11002, hPhe and Phe at the P1 and P2 positions, respectively, fit well into the respective enzyme pockets, leading to strong binding affinity and potency (Figure 1). At the P3 position, a panel of chemically different substituents was inserted and, with a few exceptions, inhibitors carrying phenyl rings were demonstrated to be very potent rhodesain inhibitors, endowed with single-digit micromolar activity against the protozoa.^{31,33} Differently from the potent vinyl sulfones K11002 and K11777, the concomitant presence of a vinyl ketone warhead and methyl-piperazine and morpholine ring at the P3 position led to poor inhibition.³³ In light of this, we assumed a strong interdependency between the methyl vinyl ketone warhead and aromatic rings at the P3 position.

Considering the impressive binding activities shown by Michael acceptors reported in Figure 1, in this new set of molecules we decided to maintain the methyl vinyl ketone warhead and the Phe-hPhe lead motif, which are well-fitted in the S2–S1 rhodesain pockets. At the P3 position, a set of variously substituted aromatic rings was inserted through an urea bond (Figure 2). The replacement of the typical peptide




Figure 1. Chemical structures of K11777, K11002, RK-52, and PS-1. Acronyms: RD, rhodesain; BSF, bloodstream form.






Figure 2. Chemical structure of designed urea derivatives 1–9.

bond with the urea function could improve the affinity and the antitrypanosomal activity. In fact, while very potent rhodesain inhibitors have been reported to date, the antitrypanosomal activity was shown to be in the micromolar or sub-micromolar range. Furthermore, the urea bond could be considered as an amide bond bioisostere, possessing more rigidity and stability.⁴⁷ In a SAR study carried out by Patrick et al., the amide-urea bond substitution led to urea derivatives with potent in vitro activity against *T. b. rhodesiense*, high metabolic stability, and moderate brain penetration.⁴⁸ Overall, variously decorated aromatic rings were inserted at the P3 position. In addition to the unsubstituted phenyl ring (1, SPR1), we decided to explore the impact of electron-donating groups (EDGs) at the *para* position (i.e., 2 (SPR2) and 3 (SPR3) carrying -OMe and -Me, respectively). The introduction of halogens led to relevant potency enhancement against rhodesain,³³ and for this reason halogen-containing phenyl rings were inserted (4 (SPR4), 5 (SPR5), and 6 (SPR6)). To

Scheme 1. Synthesis of Compounds 1–9^a

^aReagents and conditions: (a) TBTU, DIPEA, DCM, 30 min, rt, then **11**, rt, on; (b) TFA/DCM 1:1, rt, TLC monitoring; (c) Boc-Phe-OH, TBTU, DIPEA, DCM, 10 min, rt, then **13**, rt, on; (d) TEA, appropriate Ar-NCO, rt, on; (e) LiAlH₄, dry THF, 0 °C, TLC monitoring; (f) DCM, Ph₃PCHCOCH₃, rt, 2 h.


Table 1. Biological Activity of 1–9, 25, and 26 against Rhodensain and *T. b. brucei*

compd	X or Ar	Rhodensain			<i>T. b. brucei</i>
		k_{inact} (min ⁻¹)	K_i (nM)	$k_{2\text{nd}}$ ($\times 10^3$ M ⁻¹ min ⁻¹)	EC ₅₀ (μ M, 24 h)
1	H	0.0021 \pm 0.0001	0.15 \pm 0.06	16 700 \pm 6100	19.79 \pm 2.67
2	4-OMe	0.0059 \pm 0.0014	1.05 \pm 0.33	5820 \pm 490	2.08 \pm 0.22
3	4-Me	0.0023 \pm 0.0001	0.51 \pm 0.38	10 400 \pm 7800	1.39 \pm 0.23
4	4-F	0.0021 \pm 0.0002	0.85 \pm 0.07	2480 \pm 50	1.51 \pm 0.08
5	2,6-F ₂	0.0022 \pm 0.0003	1.13 \pm 0.26	2030 \pm 230	3.20 \pm 0.28
6	4-Cl	0.0023 \pm 0.0002	0.78 \pm 0.13	2990 \pm 300	1.50 \pm 0.24
7	4-Cl,2-Me	0.0053 \pm 0.0019	0.51 \pm 0.36	14 700 \pm 6400	1.65 \pm 0.07
8	4-Cl,2-CF ₃	0.0060 \pm 0.0011	1.04 \pm 0.31	6050 \pm 790	1.28 \pm 0.04
9	C ₄ H ₄	0.0084 \pm 0.0029	2.51 \pm 1.51	4170 \pm 1360	2.28 \pm 0.27
25	4-Me	0.0042 \pm 0.0001	0.42 \pm 0.08	10 360 \pm 1590	1.54 \pm 0.09
26	4-Cl,2-Me	0.0123 \pm 0.0060	0.93 \pm 0.52	13 980 \pm 1320	1.12 \pm 0.05
E64 ³⁴		0.0090 \pm 0.0004	35 \pm 5	261 \pm 27	-
K11777 ²⁸				9000	

further investigate the role played by halogens in the *para* position, disubstituted 4-chloro-2-methyl- and 4-chloro-2-CF₃-phenyl rings were introduced (**7** (SPR7) and **8** (SPR8)), because the 4-chloro-2-CF₃-phenyl ring resulted in being well-tolerated in peptidomimetic rhodensain inhibitors.^{42,49} Lastly, the aromatic region at the P3 position was further expanded through the introduction of a 1-naphthyl ring (**9**, SPR9).

The synthesis of compounds **1–9** was carried out in batches following the Boc-chemistry. With the aim to optimize our synthetic pathway previously reported, in which the dipeptidyl vinyl ketones were synthesized starting from the P1 synthon,⁵⁰ followed by the coupling with P2–P3 fragments and warhead incorporation by means of cross-metathesis,^{31,33,34} the new urea derivatives were synthesized following a different

approach (Scheme 1). Initially, the commercially available Boc-hPhe-OH **10** was coupled with *N,O*-dimethylhydroxylamine hydrochloride **11** in the presence of TBTU and DIPEA, affording the corresponding Weinreb amide **12** in high yields (91%). After that, the peptide backbone P3–P2–P1 was synthesized from the C-terminal to N-terminal portion: indeed, the subsequent TFA treatment in DCM led to the deprotected amine TFA salt **13**, which was coupled with Boc-Phe-OH. The obtained dipeptide **14** was newly treated with TFA, and the subsequent reaction with the appropriate differently substituted phenyl isocyanates in alkaline conditions by Et₃N provided the urea derivatives **16–24**. At this point, the reduction of the Weinreb amide by LiAlH₄ in dry THF led to the corresponding aldehyde analogues, which serve as

Scheme 2. Synthesis of Compounds 25 and 26^a

^aReagents and conditions: (a) Boc-Leu-OH, TBTU, DIPEA, DCM, 30 min, rt, then 13, rt, on; (b) TFA/DCM 1:1, rt, TLC monitoring; (c) TEA, appropriate Ar-NCO, rt, on; (d) LiAlH₄, dry THF, 0 °C, TLC monitoring; (e) DCM, Ph₃PCHCOCH₃, rt, 2 h.

substrates for the introduction of vinyl methyl ketone warhead by Wittig reaction with 1-(triphenylphosphoranylidene)-2-propanone. All in all, the above-described approach resulted in being widely feasible, and the final products were obtained in a shorter time, with limited use of consumables and slightly better overall yields with respect to the our previously reported synthetic method.^{31,33,34}

The biological activity of molecules 1–9 against rhodesain was determined by fluorogenic assays in the presence of the appropriate substrate (i.e., Cbz-Phe-Arg-AMC). The irreversible inhibitors could be enzymatically characterized by three kinetic parameters, namely, k_{inact} , K_i , and $k_{2\text{nd}}$, which mean the maximum potential rate of covalent bond formation, binding affinity toward the target, and potency of inhibitors, respectively. In more detail, K_i represents the dissociation constant of the noncovalent enzyme–inhibitor complex [E·I]; meanwhile, k_{inact} represents the inactivation rate constant, which defines the covalent enzyme–inhibitor complex (E-I) formation rate. Lastly, the k_{inact}/K_i ratio provides the $k_{2\text{nd}}$ value, which could be considered the best parameter to characterize irreversible inhibitors. Initially, a preliminary screening at 0.1 μM was performed, and DMSO and E-64⁵¹ were used as the negative and positive control, respectively. Considering the great inhibition shown at the screening concentration (>80%), all of the urea derivatives 1–9 were properly diluted and assayed until the minimal percentage inhibition was observed. All of the new Michael acceptors resulted in being very potent rhodesain inhibitors with K_i values in the nanomolar and sub-nanomolar range (Table 1), and 1, 3, and 7 exhibited slightly better $k_{2\text{nd}}$ values than that of K11777 reported in the literature.²⁸ The unsubstituted analogue 1 showed the best binding affinity and potency toward the target ($K_i = 0.15$ nM and $k_{2\text{nd}} = 16700 \times 10^3 \text{ M}^{-1} \text{ min}^{-1}$, respectively). Generally, the presence of substituents on the phenyl ring at the P3 position resulted in a slight decrease in binding affinity. The effect of the methyl group in 3 led to K_i and $k_{2\text{nd}}$ values that were 2-fold better with respect to the corresponding OMe-containing analogue 2, whereas 4, 5, and 6, which bear at least a halogen atom, showed similar enzyme inhibitory properties. With regard to the disubstituted analogues, while 7 exhibited a $k_{2\text{nd}}$ value comparable to that of 1, the replacement of CH₃

with CF₃ in 8 was poorly tolerated. Lastly, the extension of the aromatic region with the introduction of the 1-naphthyl ring in 9 was unproductive in terms of affinity and potency.

All the urea derivatives were tested against cultured *T. b. brucei*, which expresses rhodesain similarly to *T. b. rhodesiense*. Unexpectedly, the most potent rhodesain inhibitor 1 showed an EC₅₀ value of 19.79 μM (Table 1), whereas the remaining tested compounds exhibited antitrypanosomal activity in the low micromolar range (EC₅₀ values ranging from 1.27 to 3.19 μM). Considering the fairly flat SAR concerning the target inhibition, especially in terms of K_i values, comparable EC₅₀ values against the protozoa were analogously expected. The difference in terms of rhodesain inhibition and antitrypanosomal activity observed for 1 could be due to its poor cell membrane permeability. In fact, we assume that the presence of substituents on the phenyl ring at the P3 position, as well as the extension of the aromatic region, could influence the crossing of cell membranes.

In order to validate the role and the importance played by the urea bond and substituents at the P3 position, the Phe at the P2 site was replaced with Leu, which is highly preferred by rhodesain in this position. Considering the $k_{2\text{nd}}$ values and the antitrypanosomal activity shown by Phe-containing Michael acceptors 1–9, the 4-Me-phenyl and 4-Cl,2-Me-phenyl rings, incorporated in compounds 3 and 7, respectively, were inserted at position P3. The two new Michael acceptors 25 (SPR46) and 26 (SPR45) were synthesized with the same procedure described in Scheme 1, using Boc-Leu-OH instead of Boc-Phe-OH (Scheme 2). In the biological evaluation (Table 1), Leu-containing analogues 25 and 26 exhibited inhibitory properties comparable to those shown by Phe derivatives 3 and 7 against both rhodesain and protozoa. The introduction of Leu at the P2 site kept the activity toward the enzyme target unchanged and did not influence the cell membrane permeability. With the exception of compound 1, the ureido derivatives herein reported showed EC₅₀ values against the protozoa in the same order of magnitude of lead compounds RK-52 and PS-1,^{33,34} despite a lower inhibition toward rhodesain. This well-known discrepancy in the drug discovery process is generally ascribed to the cell permeability properties.




Figure 3. (A) Superimposition of the docked conformations of K11002 (pink) and 7 (orange) in the rhodesain binding site (blue). (B) Predicted theoretical binding pose of 7/rhodesain and their interactions. The enzyme is depicted in blue ribbons and sticks, and the ligand in orange sticks. Important residues are labeled. H-bonds are shown as red dashed lines. The images were rendered using UCSF Chimera.⁵⁵

Considering that some of our previously reported rhodesain inhibitors also showed micromolar activity against the main protease (M^{pro}) of SARS-CoV-2,⁵² the novel Michael acceptors were assayed toward the viral protease. However, in the preliminary screening carried out at 100 μ M, 1–9 exhibited a limited percentage of inhibition, ranging from 33% to 66%. In light of this, dilution assays characterizing the mode of inhibition were not performed. Since poor inhibition was shown by the Phe-containing analogues, the Leu derivatives 25 and 26 were not tested against SARS-CoV-2 M^{pro} .

All of the new urea derivatives were tested against human cathepsin L (hCatL), which shares a high percentage of sequence identity with rhodesain (Table S1). With a few exceptions, the new rhodesain inhibitors showed a marginal selectivity toward rhodesain. In particular, while comparable K_i values between rhodesain and hCatL were observed, in the latter the k_{inact} value was 1 order of magnitude less than those displayed in the assays against rhodesain. Overall, the k_{2nd} values observed for hCatL inhibition were slightly lower with respect to those against rhodesain. Even if the k_{2nd} values toward rhodesain and hCatL differ by only 1 order of magnitude, the new urea derivatives could be well tolerated in animals, due to high levels of mammalian cysteine protease and relative gene expression.^{53,54}

To gain major insight into the reasons for the rhodesain inhibitory activity of the new urea derivatives, *in silico* molecular docking calculations were performed on 1–9, 25, and 26, and the obtained data of the most active compound 7 has been reported. This compound was subjected to molecular modeling studies as it features the best compromise between *in vitro* and *in cellulo* activity among the newly described compounds. The ligand was covalently docked into rhodesain's active site using the C25 residue as an anchoring point and employing the covalent docking protocol in AutoDock4 (AD4) software (see the Supporting Information). The same technique was effectively used in other rhodesain inhibitors carrying similar Michael acceptor warheads that form the covalent bond with C25 in the rhodesain.^{31,33,34}

Indeed, the predicted binding pose for 7 was similar to the one adopted by the cocrystal K11002 ligand having the P1, P2, and P3 regions gorged at their respective enzyme clefts S1, S2, and S3 (Figure 3A) and by the other structural congeners described by us.^{31,33,34} Notably, the presence of π – π and

lipophilic interactions in the S3 pocket (Figure 3B) engaged by the 4-chloro-2-methyl-phenyl group could explain its higher inhibitory potency if compared to K11002 that features a morpholine ring in the same position. In the predicted binding pose, the methyl vinyl ketone warhead is lodged in the polar S1' subpocket, making positive contacts with H162 (Figure 3B). Here, the backbone NH of the P1 (hPhe) is involved in a H-bond interaction with the backbone CO of D161, and the phenyl ring of the P1 (hPhe) is solvent-exposed. The backbone CO of the P2 residue (Phe) is accepting a H-bond from the backbone NH of the W26 residue, while its side chain is lodged inside the hydrophobic S2 cleft that includes various hydrophobic residues such as M68, A138, A208, and L160. The urea linker forms an additional H-bond with the G66 backbone NH and allows projection of the P3 4-chloro-2-methyl-phenyl group into the S3 cleft. As already mentioned, this latter group can establish π – π interaction with F61. This contact should be reinforced by the electron-withdrawing nature of the 4-chloro group, although this effect seems to be counterbalanced by the unfavorable electrostatic interactions established by the same group with the F61 π -electron cloud. Interestingly, this should explain why compounds featuring electron-donating groups (2 and 3, see Figure S13) and more negatively charged substituents (4, Figure S13) are less potent rhodesain inhibitors. On the contrary, the 2-methyl seems to engage a positive van der Waals interaction with the L67 residue, thereby explaining why compounds featuring more polar groups such as 5 and 8 (see Figure S13) are less potent than 7. Moreover, the same methyl group seems to hamper the planar conformation of the phenylurea moiety, thereby allowing a proper fitting of the same group into the S3 cleft. All in all, while the 2-methyl substituent in 7 seems to clearly enhance the interactions with the rhodesain S3 pocket, the 4-chloro group should have a mixed effect on the ligand binding.

This would explain why 1 (see Figure S11), which features an unsubstituted phenyl ring at the P3 site, is the most proficient rhodesain inhibitor of the newly presented series. To gain further insights into the stability of the predicted binding pose and of the described molecular interactions, the 7/rhodesain complex resulting from the docking experiment was subjected to 100 ns of a molecular dynamics (MD) simulation using Desmond. In this inspection, the ligand of 7 (L-RMSD and L-RMSF) was inspected. If compared to the docking

results, the majority of the predicted ligand/protein interactions were preserved during the course of MD (see Figure S14) as 7 displayed fairly good low RMSD fluctuations (see Figure S15). The average RMSD value is 1.36 Å with a standard deviation of 0.34, whereas the average RMSF broken down atom-by-atom value is 0.89 Å with a standard deviation of 0.53, as shown in the Supporting Information (see Figure S16).

In this SAR study, a small panel of Michael acceptors was developed as potential rhodesain inhibitors and antitrypanosomal agents. The novel analogues 1–9, 25, and 26 carry a peptide backbone Phe/Leu-hPhe and the methyl vinyl ketone warhead, which represent the lead motif and reactive electrophilic portion, respectively. At the P3 position, differently decorated aromatic rings were anchored to the lead motif through a urea bond. All the urea derivatives exhibited potent inhibitory activity toward rhodesain, with K_i values in the nanomolar and sub-nanomolar ranges, and 1, 3, 7, 25, and 26 showed comparable potency to that of K11777. The substituent-containing analogues on the phenyl ring at the P3 position displayed single-digit EC_{50} values against the protozoa. No significant differences were observed when Leu was incorporated at the P2 site instead of Phe. The best compromise in terms of activity against both the enzyme and protozoa was observed in 7, which showed potent rhodesain inhibition and EC_{50} values in the low micromolar range. In the future, compound 7 could represent an interesting lead compound for further investigation of the S3 rhodesain pocket and the development of rhodesain inhibitors and anti-HAT agents.

■ ASSOCIATED CONTENT

SI Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acsmmedchemlett.2c00084>.

Detailed description of the synthesis of the intermediates and final products, and relative characterization; description of the biological evaluation toward rhodesain, SARS-CoV-2 M^{pro} , hCatL and protozoan; detailed description of the molecular modeling procedures docking results, molecular dynamics analysis; NMR spectra of the final compounds. hCatL biological activity (PDF)

■ AUTHOR INFORMATION

Corresponding Author

Santo Previti – Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy; orcid.org/0000-0001-8473-3321; Phone: +39 090 676 6411; Email: spreviti@unime.it

Authors

Roberta Ettari – Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy; orcid.org/0000-0001-9020-2068

Elsa Calcaterra – Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy

Carla Di Chio – Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy

Rahul Ravichandran – DiSTABiF, University of Campania “Luigi Vanvitelli”, 81100 Caserta, Italy

Collin Zimmer – Institute of Pharmaceutical and Biomedical Sciences, University of Mainz, 55128 Mainz, Germany

Stefan Hammerschmidt – Institute of Pharmaceutical and Biomedical Sciences, University of Mainz, 55128 Mainz, Germany

Annika Wagner – Institute of Organic Chemistry & Macromolecular Chemistry, Friedrich-Schiller-University of Jena, 07743 Jena, Germany

Marta Bogacz – Institute of Organic Chemistry & Macromolecular Chemistry, Friedrich-Schiller-University of Jena, 07743 Jena, Germany

Sandro Cosconati – DiSTABiF, University of Campania “Luigi Vanvitelli”, 81100 Caserta, Italy; orcid.org/0000-0002-8900-0968

Tanja Schirmeister – Institute of Pharmaceutical and Biomedical Sciences, University of Mainz, 55128 Mainz, Germany

Maria Zappalà – Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy; orcid.org/0000-0002-8942-797X

Complete contact information is available at:

<https://pubs.acs.org/doi/10.1021/acsmmedchemlett.2c00084>

Author Contributions

S.P.: Synthesis, investigation, characterization, writing—original draft. R.E.: Validation, review, and editing. E.C.: Synthesis. C.D.C.: Rhodesain biological investigation. R.R.: Molecular docking investigation. C.Z.: Rhodesain expression, review, and editing. S.H.: SARS-CoV-2 M^{pro} investigation. A.W.: Trypanosoma biological investigation, review, and editing. M.B.: Trypanosoma biological investigation. S.C.: Molecular docking data validation and writing, review, and editing. T.S.: Validation, review, and editing. M.Z.: Validation, funding acquisition, supervision, review, and editing. All authors have given approval to the final version of the manuscript.

Funding

M.Z. acknowledges FFABR 2020 of the University of Messina for financially support this work. M.Z. also acknowledges the Italian Ministry of University and Research (Grant No. FISR2020IIP_00850) for financially supporting the screening of the inhibitors against the main protease of SARS-CoV-2.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

S.P. thanks U. Hellmich for fruitful discussions.

■ ABBREVIATIONS

HAT, Human African Trypanosomiasis; NTS, Neglected Tropical Disease; BBB, blood-brain barrier; CNS, central nervous system; FDA, U.S. Food and Drug Administration; WHO, World Health Organization; DNDi, Drugs for Neglected Diseases Initiative; NECT, Nifurtimox-Eflornithine Combination Therapy; PDB, Protein Data Bank; SAR, structure–activity relationship; EDG, electron-donating

group; AMC, 7-Amino-4-methylcoumarin; hCatL, human Cathepsin L.

REFERENCES

- (1) World Health Organization. *Human African Trypanosomiasis (sleeping sickness)*. World Health Organization, 2021 https://www.who.int/trypanosomiasis_african/en/ (accessed January 22, 2022).
- (2) Büscher, P.; Cecchi, G.; Jamonneau, V.; Priotto, G. Human African Trypanosomiasis. *Lancet* **2017**, *390* (10110), 2397–2409.
- (3) Rijo-Ferreira, F.; Takahashi, J. S. Sleeping sickness: a tale of two clocks. *Front Cell Infect Microbiol* **2020**, *10*, 525097.
- (4) Kennedy, P. G. E.; Rodgers, J. Clinical and neuropathogenetic aspects of Human African Trypanosomiasis. *Front Immunol* **2019**, *10*, 39.
- (5) Trindade, S.; Rijo-Ferreira, F.; Carvalho, T.; Pinto-Neves, D.; Guegan, F.; Aresta-Branco, F.; Bento, F.; Young, S. A.; Pinto, A.; Van Den Abbeele, J.; Ribeiro, R. M.; Dias, S.; Smith, T. K.; Figueiredo, L. M. Trypanosoma brucei parasites occupy and functionally adapt to the adipose tissue in mice. *Cell Host Microbe* **2016**, *19* (6), 837–848.
- (6) Malvy, D.; Chappuis, F. Sleeping sickness. *Clin Microbiol Infect* **2011**, *17* (7), 986–995.
- (7) Mulenga, C.; Mhlanga, J. D.; Kristensson, K.; Robertson, B. Trypanosoma brucei brucei crosses the blood-brain barrier while tight junction proteins are preserved in a rat chronic disease model. *Neuropathol Appl Neurobiol* **2001**, *27* (1), 77–85.
- (8) Mogk, S.; Bosselmann, C. M.; Mudogo, C. N.; Stein, J.; Wolburg, H.; Duszenko, M. African trypanosomes and brain infection - the unsolved question. *Biol. Rev. Camb Philos. Soc.* **2017**, *92* (3), 1675–1687.
- (9) Checchi, F.; Filipe, J. A.; Haydon, D. T.; Chandramohan, D.; Chappuis, F. Estimates of the duration of the early and late stage of gambiense sleeping sickness. *BMC Infect. Dis.* **2008**, *8* (1), 16.
- (10) Babokhov, P.; Sanyaolu, A. O.; Oyibo, W. A.; Fagbenro-Beyioku, A. F.; Iriemenam, N. C. A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis. *Pathog Glob Health* **2013**, *107* (5), 242–252.
- (11) De Koning, H. P. The Drugs of Sleeping Sickness: Their Mechanisms of Action and Resistance, and a Brief History. *Trop. Med. Infect. Dis.* **2020**, *5* (1), 14.
- (12) Deeks, E. D. Fexinidazole: first global approval. *Drugs* **2019**, *79* (2), 215–220.
- (13) Mullard, A. FDA approves first all-oral sleeping sickness drug. *Nat. Rev. Drug Discovery* **2021**, *20* (9), 658.
- (14) Gao, J. M.; Qian, Z. Y.; Hide, G.; Lai, D. H.; Lun, Z. R.; Wu, Z. D. Human African trypanosomiasis: the current situation in endemic regions and the risks for non-endemic regions from imported cases. *Parasitology* **2020**, *147* (9), 922–931.
- (15) Sudarshi, D.; Brown, M. Human African trypanosomiasis in non-endemic countries. *Clin Med.* **2015**, *15* (1), 70–73.
- (16) Shah, V. V.; Patel, V. M.; Vyas, P. Human African Trypanosomiasis - A rare case report from India. *Indian J. Med. Microbiol* **2022**, *40*, 169–171.
- (17) Navarro, M.; Justo, R. M. S.; Delgado, G. Y. S.; Visbal, G. Metallodrugs for the treatment of trypanosomatid diseases: Recent advances and new insights. *Curr. Pharm. Des* **2021**, *27* (15), 1763–1789.
- (18) Previti, S.; Di Chio, C.; Ettari, R.; Zappalà, M. Dual inhibition of parasitic targets: a valuable strategy to treat malaria and neglected tropical diseases. *Curr. Med. Chem.* **2022**, *29* (17), 2952–2978.
- (19) Lee, S. M.; Kim, M. S.; Hayat, F.; Shin, D. Recent advances in the discovery of novel antiprotozoal agents. *Molecules* **2019**, *24* (21), 3886.
- (20) Ettari, R.; Previti, S.; Tamborini, L.; Cullia, G.; Grasso, S.; Zappalà, M. The inhibition of cysteine proteases rhodesain and TbCatB: a valuable approach to treat Human African Trypanosomiasis. *Mini Rev. Med. Chem.* **2016**, *16* (17), 1374–1391.
- (21) Ferreira, L. G.; Andricopulo, A. D. Targeting cysteine proteases in trypanosomatid disease drug discovery. *Pharmacol Ther* **2017**, *180*, 49–61.
- (22) Ettari, R.; Tamborini, L.; Angelo, I. C.; Micale, N.; Pinto, A.; De Micheli, C.; Conti, P. Inhibition of rhodesain as a novel therapeutic modality for human African trypanosomiasis. *J. Med. Chem.* **2013**, *56* (14), 5637–5658.
- (23) Steverding, D.; Caffrey, C. R. Should the enzyme name 'rhodesain' be discontinued? *Mol. Biochem. Parasitol.* **2021**, *245*, 111395.
- (24) Nikolskaia, O. V.; de Lima, A. A. P.; Kim, Y. V.; Lonsdale-Eccles, J. D.; Fukuma, T.; Scharfstein, J.; Grab, D. J. Blood-brain barrier traversal by African trypanosomes requires calcium signaling induced by parasite cysteine protease. *J. Clin Invest* **2006**, *116* (10), 2739–2747.
- (25) Grab, D. J.; Garcia-Garcia, J. C.; Nikolskaia, O. V.; Kim, Y. V.; Brown, A.; Pardo, C. A.; Zhang, Y.; Becker, K. G.; Wilson, B. A.; de, A. L. A. P.; Scharfstein, J.; Dumler, J. S. Protease activated receptor signaling is required for African trypanosome traversal of human brain microvascular endothelial cells. *PLoS Negl. Trop. Dis.* **2009**, *3* (7), No. e479.
- (26) Kerr, I. D.; Wu, P.; Marion-Tsukamaki, R.; Mackey, Z. B.; Brinen, L. S. Crystal Structures of TbCatB and rhodesain, potential chemotherapeutic targets and major cysteine proteases of Trypanosoma brucei. *PLoS Negl Trop Dis* **2010**, *4* (6), No. e701.
- (27) Johe, P.; Jaenicke, E.; Neuweiler, H.; Schirmeister, T.; Kersten, C.; Hellmich, U. A. Structure, interdomain dynamics, and pH-dependent autoactivation of pro-rhodesain, the main lysosomal cysteine protease from African trypanosomes. *J. Biol. Chem.* **2021**, *296*, 100565.
- (28) Kerr, I. D.; Lee, J. H.; Farady, C. J.; Marion, R.; Rickert, M.; Sajid, M.; Pandey, K. C.; Caffrey, C. R.; Legac, J.; Hansell, E.; McKerrow, J. H.; Craik, C. S.; Rosenthal, P. J.; Brinen, L. S. Vinyl sulfones as antiparasitic agents and a structural basis for drug design. *J. Biol. Chem.* **2009**, *284* (38), 25697–25703.
- (29) Breuning, A.; Degel, B.; Schulz, F.; Buchold, C.; Stempka, M.; Machon, U.; Heppner, S.; Gelhaus, C.; Leippe, M.; Leyh, M.; Kisker, C.; Rath, J.; Stich, A.; Gut, J.; Rosenthal, P. J.; Schmuck, C.; Schirmeister, T. Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids. *J. Med. Chem.* **2010**, *53* (5), 1951–1963.
- (30) Bryant, C.; Kerr, I. D.; Debnath, M.; Ang, K. K.; Ratnam, J.; Ferreira, R. S.; Jaishankar, P.; Zhao, D.; Arkin, M. R.; McKerrow, J. H.; Brinen, L. S.; Renslo, A. R. Novel non-peptidic vinylsulfones targeting the S2 and S3 subsites of parasite cysteine proteases. *Bioorg. Med. Chem. Lett.* **2009**, *19* (21), 6218–6221.
- (31) Maiorana, S.; Ettari, R.; Previti, S.; Amendola, G.; Wagner, A.; Cosconati, S.; Hellmich, U. A.; Schirmeister, T.; Zappalà, M. Peptidyl vinyl ketone irreversible inhibitors of rhodesain: modifications of the P2 fragment. *ChemMedChem.* **2020**, *15* (16), 1552–1561.
- (32) Di Chio, C.; Previti, S.; Amendola, G.; Cosconati, S.; Schirmeister, T.; Zappalà, M.; Ettari, R. Development of novel benzodiazepine-based peptidomimetics as inhibitors of rhodesain from Trypanosoma brucei rhodesiense. *ChemMedChem.* **2020**, *15* (11), 995–1001.
- (33) Ettari, R.; Previti, S.; Maiorana, S.; Amendola, G.; Wagner, A.; Cosconati, S.; Schirmeister, T.; Hellmich, U. A.; Zappalà, M. Optimization strategy of novel peptide-based Michael acceptors for the treatment of Human African Trypanosomiasis. *J. Med. Chem.* **2019**, *62* (23), 10617–10629.
- (34) Previti, S.; Ettari, R.; Cosconati, S.; Amendola, G.; Chouchene, K.; Wagner, A.; Hellmich, U. A.; Ulrich, K.; Krauth-Siegel, R. L.; Wich, P. R.; Schmid, I.; Schirmeister, T.; Gut, J.; Rosenthal, P. J.; Grasso, S.; Zappalà, M. Development of novel peptide-based Michael acceptors targeting rhodesain and falcipain-2 for the treatment of Neglected Tropical Diseases (NTDs). *J. Med. Chem.* **2017**, *60* (16), 6911–6923.
- (35) Ettari, R.; Previti, S.; Cosconati, S.; Maiorana, S.; Schirmeister, T.; Grasso, S.; Zappalà, M. Development of novel 1,4-benzodiazepine-based Michael acceptors as antitrypanosomal agents. *Bioorg. Med. Chem. Lett.* **2016**, *26* (15), 3453–3456.

- (36) Jung, S.; Fuchs, N.; Johe, P.; Wagner, A.; Diehl, E.; Yuliani, T.; Zimmer, C.; Barthels, F.; Zimmermann, R. A.; Klein, P.; Waigel, W.; Meyr, J.; Opatz, T.; Tenzer, S.; Distler, U.; Rader, H. J.; Kersten, C.; Engels, B.; Hellmich, U. A.; Klein, J.; Schirmeister, T. Fluorovinyl-sulfones and -sulfonates as potent covalent reversible inhibitors of the trypanosomal cysteine protease rhodesain: structure-activity relationship, inhibition mechanism, metabolism, and in vivo studies. *J. Med. Chem.* **2021**, *64* (16), 12322–12358.
- (37) Giroud, M.; Kuhn, B.; Saint-Auret, S.; Kuratli, C.; Martin, R. E.; Schuler, F.; Diederich, F.; Kaiser, M.; Brun, R.; Schirmeister, T.; Haap, W. 2 H-1,2,3-Triazole-based dipeptidyl nitriles: potent, selective, and trypanocidal rhodesain inhibitors by structure-based design. *J. Med. Chem.* **2018**, *61* (8), 3370–3388.
- (38) Schirmeister, T.; Schmitz, J.; Jung, S.; Schmenger, T.; Krauth-Siegel, R. L.; Gutschow, M. Evaluation of dipeptide nitriles as inhibitors of rhodesain, a major cysteine protease of *Trypanosoma brucei*. *Bioorg. Med. Chem. Lett.* **2017**, *27* (1), 45–50.
- (39) Ettari, R.; Pinto, A.; Previti, S.; Tamborini, L.; Angelo, I. C.; La Pietra, V.; Marinelli, L.; Novellino, E.; Schirmeister, T.; Zappalà, M.; Grasso, S.; De Micheli, C.; Conti, P. Development of novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation. *Bioorg. Med. Chem.* **2015**, *23* (21), 7053–7060.
- (40) Ettari, R.; Pinto, A.; Tamborini, L.; Angelo, I. C.; Grasso, S.; Zappalà, M.; Capodicasa, N.; Yzeiraj, L.; Gruber, E.; Aminake, M. N.; Pradel, G.; Schirmeister, T.; De Micheli, C.; Conti, P. Synthesis and biological evaluation of papain-family cathepsin L-like cysteine protease inhibitors containing a 1,4-benzodiazepine scaffold as antiprotozoal agents. *ChemMedChem* **2014**, *9* (8), 1817–1825.
- (41) Ettari, R.; Previti, S.; Cosconati, S.; Kesselring, J.; Schirmeister, T.; Grasso, S.; Zappalà, M. Synthesis and biological evaluation of novel peptidomimetics as rhodesain inhibitors. *J. Enzyme Inhib Med. Chem.* **2016**, *31* (6), 1184–1191.
- (42) Ettari, R.; Tamborini, L.; Angelo, I. C.; Grasso, S.; Schirmeister, T.; Lo Presti, L.; De Micheli, C.; Pinto, A.; Conti, P. Development of rhodesain inhibitors with a 3-bromoisoxazoline warhead. *ChemMedChem* **2013**, *8* (12), 2070–2076.
- (43) Latorre, A.; Schirmeister, T.; Kesselring, J.; Jung, S.; Johe, P.; Hellmich, U. A.; Heilos, A.; Engels, B.; Krauth-Siegel, R. L.; Dirdjaja, N.; Bou-Iserte, L.; Rodriguez, S.; Gonzalez, F. V. Dipeptidyl nitroalkenes as potent reversible inhibitors of cysteine proteases rhodesain and cruzain. *ACS Med. Chem. Lett.* **2016**, *7* (12), 1073–1076.
- (44) Mallari, J. P.; Shelat, A.; Kosinski, A.; Caffrey, C. R.; Connelly, M.; Zhu, F.; McKerrow, J. H.; Guy, R. K. Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcA. *Bioorg. Med. Chem. Lett.* **2008**, *18* (9), 2883–2885.
- (45) Klein, P.; Johe, P.; Wagner, A.; Jung, S.; Kuhlborn, J.; Barthels, F.; Tenzer, S.; Distler, U.; Waigel, W.; Engels, B.; Hellmich, U. A.; Opatz, T.; Schirmeister, T. New cysteine protease inhibitors: electrophilic (het)arenes and unexpected prodrug identification for the *Trypanosoma* protease rhodesain. *Molecules* **2020**, *25* (6), 1451.
- (46) Di Chio, C.; Previti, S.; Amendola, G.; Ravichandran, R.; Wagner, A.; Cosconati, S.; Hellmich, U. A.; Schirmeister, T.; Zappalà, M.; Ettari, R. Development of novel dipeptide nitriles as inhibitors of rhodesain of *Trypanosoma brucei rhodesiense*. *Eur. J. Med. Chem.* **2022**, *236*, 114328.
- (47) Kumari, S.; Carmona, A. V.; Tiwari, A. K.; Trippier, P. C. Amide bond bioisosteres: Strategies, synthesis, and successes. *J. Med. Chem.* **2020**, *63* (21), 12290–12358.
- (48) Patrick, D. A.; Wenzler, T.; Yang, S.; Weiser, P. T.; Wang, M. Z.; Brun, R.; Tidwell, R. R. Synthesis of novel amide and urea derivatives of thiazol-2-ethylamines and their activity against *Trypanosoma brucei rhodesiense*. *Bioorg. Med. Chem.* **2016**, *24* (11), 2451–2465.
- (49) Ettari, R.; Zappalà, M.; Micale, N.; Schirmeister, T.; Gelhaus, C.; Leippe, M.; Evers, A.; Grasso, S. Synthesis of novel peptidomimetics as inhibitors of protozoan cysteine proteases falcipain-2 and rhodesain. *Eur. J. Med. Chem.* **2010**, *45* (7), 3228–3233.
- (50) Ettari, R.; Nizi, E.; Di Francesco, M. E.; Dude, M. A.; Pradel, G.; Vicik, R.; Schirmeister, T.; Micale, N.; Grasso, S.; Zappalà, M. Development of peptidomimetics with a vinyl sulfone warhead as irreversible falcipain-2 inhibitors. *J. Med. Chem.* **2008**, *51* (4), 988–996.
- (51) Matsumoto, K.; Mizoue, K.; Kitamura, K.; Tse, W. C.; Huber, C. P.; Ishida, T. Structural basis of inhibition of cysteine proteases by E-64 and its derivatives. *Biopolymers* **1999**, *51* (1), 99–107.
- (52) Amendola, G.; Ettari, R.; Previti, S.; Di Chio, C.; Messere, A.; Di Maro, S.; Hammerschmidt, S. J.; Zimmer, C.; Zimmermann, R. A.; Schirmeister, T.; Zappalà, M.; Cosconati, S. Lead discovery of SARS-CoV-2 main protease inhibitors through covalent docking-based virtual screening. *J. Chem. Inf Model* **2021**, *61* (4), 2062–2073.
- (53) Ang, K. K. H.; Ratnam, J.; Gut, J.; Legac, J.; Hansell, E.; Mackey, Z. B.; Skrzypczynska, K. M.; Debnath, A.; Engel, J. C.; Rosenthal, P. J.; McKerrow, J. H.; Arkin, M. R.; Renslo, A. R. Mining a cathepsin inhibitor library for new antiparasitic drug leads. *PLOS Neg Trop Dis* **2011**, *5* (5), No. e1023.
- (54) Scory, S.; Caffrey, C. R.; Stierhof, Y. D.; Ruppel, A.; Steverding, D. *Trypanosoma brucei*: killing of bloodstream forms in vitro and in vivo by the cysteine proteinase inhibitor Z-Phe-Ala-CHN2. *Exp Parasitol* **1999**, *91* (4), 327–333.
- (55) Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera—a visualization system for exploratory research and analysis. *J. Comput. Chem.* **2004**, *25* (13), 1605–1612.